Polymyositis

Type: Keyphrase
Name: Polymyositis
First reported Apr 20 2014 - Updated Apr 20 2014 - 1 reports

Auto-Immune Self-Care Board?

Hi board community,I am posting in the autoimmune forum, because I am waiting for my initial visit with a rheumatologist. Lab work was: ANA 1,280, positive for rheumatoid factor, low level of c-reactive protein. Symptoms: Hand and wrist arthritis, swelling ... [Published HealthBoards - Apr 20 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Antinuclear-Antibody Testing Analyzed by Automated Indirect Immunofluorescence

Image: Fluorescence antinuclear antibody speckled pattern staining (Photo courtesy of the Autoantibody Standardization Committee).Automated quantitative reading of fluorescence intensity has been evaluated for clinical relevance which allows for value-added ... [Published Lab Medica - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Biomarkers in CTD-Associated Interstitial Lung Disease

Olson AL, Brown KK, Fischer A. Connective tissue disease-associated lung disease. Immunol Allergy Clin North Am 2012; 32 (4) 513–536Launay D, Remy-Jardin M, Michon-Pasturel U, et al. High resolution computed tomography in fibrosing alveolitis associated ... [Published General Medicine eJournal - Apr 14 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 3 reports

Idera Soars on Phase II Drug Data - Analyst Blog

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) shares jumped 17.78% after the company announced positive top-line data from a phase II study on its lead pipeline candidate, IMO-8400, an antagonist of toll-like receptors (TLRs) 7, 8, and 9.The randomized, ... [Published Benzinga.com - Apr 01 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 4 reports

Psoriasis Drug Shows Promise in Mid-Stage Trial

Toll-like receptor antagonist meets primary endpoint of safety and tolerabilityPositive results have been reported from a randomized, double-blind, placebo-controlled phase II trial of IMO-8400 (Idera Pharmaceuticals) in 32 patients with moderate-to-severe ... [Published P&T Community - Mar 28 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Idera spikes as its up-and-down TLR program comes through in PhII

Idera Pharmaceuticals CEO Sudhir AgrawalAfter setbacks in cancer and respiratory disease, Idera Pharmaceuticals ($IDRA) has finally found some success with its toll-like receptor (TLR) program, touting encouraging results from a Phase II trial on autoimmune ... [Published FierceBiotech - Mar 28 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

Refractory Myositis: What Can Be Done?

Treating the idiopathic inflammatory myopathies can be challenging. These rare and heterogenous diseases do not lend themselves well to the large randomized trials that guide treatment standards. Other than corticosteroids and adrenocorticotropin (ACTH) ... [Published Consultant Live - Mar 26 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

A crucial role of L-selectin in C protein-induced experimental polymyositis of mice

AbstractObjective. To investigate the role of adhesion molecules in C protein-induced myositis (CIM), a murine model for polymyositis (PM).Methods. CIM was induced in wild type mice, L-selectin-deficient (L-selectin -/- ) mice, ICAM-1-deficient (ICAM-1 ... [Published Arthritis & Rheumatism - Mar 19 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

IDERA PHARMACEUTICALS : to Initiate Clinical Development of IMO-8400 for Polymyositis and Dermatomyositis

Idera Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, announced that it plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan ... [Published 4 Traders - Mar 18 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

Idera Pharmaceuticals announces expansion of pipeline into two orphan autoimmune diseases

Idera Pharmaceuticals plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune ... ... [Published Big News Network - Mar 14 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

Idera Pharmaceuticals announces expansion of pipeline into two orphan autoimmune diseases

Idera Pharmaceuticals plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs.The company plans ... [Published Pharmaceutical Business Review - Mar 14 2014]
First reported Mar 13 2014 - Updated Mar 13 2014 - 3 reports

Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell ... [Published EON Science - Mar 13 2014]

Quotes

...in the treatment of patients suffering from idiopathic types of nephrotic syndrome," said Steve Cartt , Chief Operating Officer of Questcor.   "As a company, we continue to actively support both company-sponsored research and independent academic research evaluating Acthar in on-label indications such as the one studied in this trial, as well as in other autoimmune and inflammatory disorders having high unmet medical need."
Mark Trudeau, president and chief executive officer of Mallinckrodt, said, "We believe this transaction will provide a strong and sustainable platform for future revenue and earnings growth, and provide exceptional value for shareholders of both Mallinckrodt and Questcor. It will substantially increase the scale, diversification, cash flow and profitability of our business, while expanding and enhancing the breadth and depth of our specialty pharmaceutical platform.  With Questcor, combined with our recently completed acquisition of Cadence Pharmaceuticals, the new Mallinckrodt will have a significant, established presence with prescribers, payers and hospitals. We will also have an increasingly diversified specialty pharmaceuticals portfolio, which will include novel therapeutics for pain management, as well as central nervous system, renal, rheumatologic and other autoimmune and inflammatory disorders."
...CEO of Idera Pharmaceuticals. "With these data, we can now pursue our announced business strategy and advance our TLR antagonist drug candidates for the treatment of orphan diseases with high unmet medical need. Towards this goal, our clinical development strategy for IMO-8400 is focused on B-cell lymphomas harboring the MYD88 L265P mutation, and on orphan autoimmune disease indications. Over the remainder of 2014, we anticipate enrolling patients in IMO-8400 trials for Waldenstrom's macroglobulinemia, diffuse large B-cell lymphoma and polymyositis and dermatomyositis."
...indication to demonstrate clinical proof of concept for our TLR antagonists in autoimmune diseases," CEO Sudhir Agrawal said in a statement. "With these data, we can now pursue our announced business strategy and advance our TLR antagonist drug candidates for the treatment of orphan diseases with high unmet medical need."

More Content

All (39) | News (33) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Clinical Trial Results Indicate Acthar May Sign... [Published ADVFN India - Apr 21 2014]
Auto-Immune Self-Care Board? [Published HealthBoards - Apr 20 2014]
Targeted transforming growth factor-beta-bound ... [Published PharmCast - Apr 17 2014]
Antinuclear-Antibody Testing Analyzed by Automa... [Published Lab Medica - Apr 15 2014]
Biomarkers in CTD-Associated Interstitial Lung ... [Published General Medicine eJournal - Apr 14 2014]
Inhibition of Myogenic MicroRNAs 1, 133, and 20... [Published Arthritis & Rheumatism - Apr 08 2014]
Mallinckrodt to acquire Questcor Pharmaceutical... [Published PharmaBiz - Apr 08 2014]
Idera Pharmaceuticals announces positive data f... [Published PredictWallStreet - Apr 07 2014]
Idera Pharmaceuticals Announces Positive Top-li... [Published Drugs.com - Apr 03 2014]
Idera Soars on Phase II Drug Data - Analyst Blog [Published Benzinga.com - Apr 01 2014]
Idera Soars on Phase II Drug Data [Published Zacks.com - Mar 31 2014]
Idera Says Drug Safe, Well Tolerated in Skin Di... [Published American Journal of Public Health - Mar 31 2014]
Psoriasis Drug Shows Promise in Mid-Stage Trial [Published P&T Community - Mar 28 2014]
IDERA PHARMACEUTICALS : IDRA) Climbs on Positiv... [Published 4 Traders - Mar 28 2014]
Idera spikes as its up-and-down TLR program com... [Published FierceBiotech - Mar 28 2014]
Idera Pharma Reports Positive Top-line Data Fro... [Published RTTNews.com - Mar 28 2014]
Idera Pharmaceuticals Announces Positive Top-li... [Published BusinessWeek - Mar 28 2014]
Refractory Myositis: What Can Be Done? [Published Consultant Live - Mar 26 2014]
In NEJM This Week: Vascular Complications of Rh... [Published Consultant Live - Mar 24 2014]
BIO RAD LABORATORIES : Patent Application Title... [Published 4 Traders - Mar 19 2014]
Researchers Submit Patent Application, "Agents ... [Published HispanicBusiness.com - Mar 19 2014]
A crucial role of L-selectin in C protein-induc... [Published Arthritis & Rheumatism - Mar 19 2014]
IDERA PHARMACEUTICALS : to Initiate Clinical De... [Published 4 Traders - Mar 18 2014]
Idera Pharmaceuticals announces expansion of pi... [Published Big News Network - Mar 14 2014]
Idera Pharmaceuticals announces expansion of pi... [Published Pharmaceutical Business Review - Mar 14 2014]
Idera Pharmaceuticals Announces Expansion of Pi... [Published EON Science - Mar 13 2014]
Idera Pharmaceuticals Announces Expansion of Pi... [Published Business Wire Science: Science News - Mar 13 2014]
Idera Pharmaceuticals Announces Expansion of Pi... [Published Business Wire Health News - Mar 13 2014]
Anyone knowledgeable about scleroderma? [Published HealthBoards - Mar 05 2014]
Delivery system for cytotoxic drugs by bispecif... [Published PharmCast - Mar 02 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Auto-Immune Self-Care Board? [Published HealthBoards - Apr 20 2014]
Hi board community,I am posting in the autoimmune forum, because I am waiting for my initial visit with a rheumatologist. Lab work was: ANA 1,280, positive for rheumatoid factor, low level of c-reactive protein. Symptoms: Hand and wrist arthritis, swelling ...
Idera Pharmaceuticals Announces Expansion of Pi... [Published EON Science - Mar 13 2014]
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell ...
Idera Pharmaceuticals Announces Expansion of Pi... [Published Business Wire Science: Science News - Mar 13 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, ...
Idera Pharmaceuticals Announces Expansion of Pi... [Published Business Wire Health News - Mar 13 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, ...
Anyone knowledgeable about scleroderma? [Published HealthBoards - Mar 05 2014]
Hi,I have been diagnosed with RA, Polymyositis, and Raynauds. While I am and have been so sick while taking the cellcept and prednisone, it is nothing compared to all the illnesses I have caught in my immune suppressed state. Not to mention the anxiety ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.